National University of Malaysia

ukm.my

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

117

Active

35

Phase 3

5

Total enrollment

13,682

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
CD19 CAR-T cells————2
Cyclophosphamide—————1
Fludarabine—————1
Silver diamine fluoride- potassium iodide—————1
Fluoride varnish—————1
Gentamicin - single dose—————1
Distilled water—————1
CAR-T cells—————1
Autologous dentin graft—————1
Xenograft—————1
Hydroxychloroquine Oral—————1
Intrapleural t-PA/Dnase arm—————1
t-PA (Alteplase) 5-10mg and Tyloxapol 200mg—————1
Heparin saline lock—————1
Syrup Prospan—————1
N-Acetylcysteine—————1

Next readouts

  • 2025-06-02
  • 2026-06-01
  • 2026-07-08
  • 2026-08-31
  • 2026-11-30
  • 2027-01-18
  • 2027-03-01
  • 2027-11-30
  • 2028-06-01
  • 2028-12-02

Top conditions

  • Gestational Diabetes3
  • Pleural Effusion3
  • Endophthalmitis Postoperative2
  • Type 2 Diabetes2
  • IVF2
  • Trigger Finger2
  • Rhinitis, Allergic2
  • Choledocholithiasis2

Frequently asked questions about National University of Malaysia

How many clinical trials does National University of Malaysia have on ClinicalTrials.gov?
National University of Malaysia is listed as the lead sponsor on 117 clinical trials in ClinicalTrials.gov, 35 of which are currently active (recruiting, enrolling, or ongoing).
How many of National University of Malaysia's trials are in Phase 3?
5 of National University of Malaysia's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does National University of Malaysia focus on?
National University of Malaysia's most-studied conditions on ClinicalTrials.gov are Gestational Diabetes, Pleural Effusion, Endophthalmitis Postoperative, Type 2 Diabetes, IVF.
When are National University of Malaysia's next clinical trial readouts?
National University of Malaysia has 10 upcoming primary-completion readouts tracked here; the soonest is “To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)”, expected around 2025-06-02.